Literature DB >> 6283885

Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP): update on studies of the registry.

D T Purtilo, K Sakamoto, V Barnabei, J Seeley, T Bechtold, G Rogers, J Yetz, S Harada.   

Abstract

Analyses of 100 subjects with the X-linked lymphoproliferative syndrome (XLP) in 25 kindreds revealed four major interrelated phenotypes: infectious mononucleosis, malignant B-cell lymphoma, aplastic anemia, and hypogammaglobulinemia. Eighty-one of the patients died. Two male subjects were asymptomatic but showed immunodeficiency to Epstein-Barr virus (EBV). Seventy-five subjects had the infectious mononucleosis phenotype and concurrently, 17 subjects of this group had aplastic anemia. All subjects with aplastic anemia died within a week. Aplastic anemia did not accompany hypogammaglobulinemia or malignant lymphoma phenotypes. Hypogammaglobulinemia had been detected before infectious mononucleosis in three subjects, after infectious mononucleosis in five subjects, and was not associated with infectious mononucleosis in 11 boys with hypogammaglobulinemia. In nine subjects infectious mononucleosis appeared to have evolved into malignant lymphoma; however, the majority of patients with malignant lymphoma showed no obvious antecedent infectious mononucleosis. One subject had infectious mononucleosis following recurrent malignant lymphoma. Twenty-six of 35 lymphomas were in the terminal ileum. Results of immunologic and virologic studies of 15 survivors revealed combined variable immunodeficiency and deficient antibody responses to EBV-specific antigens. Mothers of boys with XLP exhibited abnormally elevated titers of antibodies of EBV. Subjects of both sexes with phenotypes of XLP should be investigated for immunodeficiency to EBV. Persons with inherited or acquired immunodeficiency may be vulnerable to life-threatening EBV-induced diseases.

Entities:  

Mesh:

Year:  1982        PMID: 6283885     DOI: 10.1016/0002-9343(82)90923-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  17 in total

1.  Epstein-Barr virus specific antibodies in patients with coeliac disease.

Authors:  S Harada; J Greally; J Davis; N Synder; F Stevens; C McCarthy; D T Purtilo
Journal:  Ir J Med Sci       Date:  1985-11       Impact factor: 1.568

Review 2.  X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology.

Authors:  D T Purtilo
Journal:  Springer Semin Immunopathol       Date:  1991

3.  Aplastic anemia complicating infectious mononucleosis.

Authors:  C A Sawka; J A Bessette; B Furie; J F Desforges
Journal:  CMAJ       Date:  1987-04-01       Impact factor: 8.262

Review 4.  Clinical consequences of Epstein-Barr virus infection and possible control by an anti-viral vaccine.

Authors:  M A Epstein; A J Morgan
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

5.  Defective control of Epstein-Barr virus-infected B cell growth in patients with X-linked lymphoproliferative disease.

Authors:  N Yasuda; P K Lai; J Rogers; D T Purtlo
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

Review 6.  XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP.

Authors:  Stuart G Tangye
Journal:  J Clin Immunol       Date:  2014-08-02       Impact factor: 8.317

7.  Mapping the X-linked lymphoproliferative syndrome.

Authors:  J C Skare; A Milunsky; K S Byron; J L Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

8.  Lytic, nontransforming Epstein-Barr virus (EBV) from a patient with chronic active EBV infection.

Authors:  C Alfieri; F Ghibu; J H Joncas
Journal:  Can Med Assoc J       Date:  1984-11-15       Impact factor: 8.262

9.  Heterogeneity of immune defects in three children with a chronic active Epstein-Barr virus infection.

Authors:  W Kuis; J J Roord; B J Zegers; A B Rickinson; J G Kapsenberg; H The; J W Stoop
Journal:  J Clin Immunol       Date:  1985-11       Impact factor: 8.317

10.  Activation of the Epstein-Barr virus replicative cycle by human herpesvirus 6.

Authors:  L Flamand; I Stefanescu; D V Ablashi; J Menezes
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.